Interaction between CD44 and hyaluronate induces chemoresistance in non-small cell lung cancer cell

Cancer Letters

Volumn 252, Issue 2, 2007, Pages 225-234

  Ohashi, Rina ^a   Takahashi, Fumiyuki ^a   Cui, Ri ^a   Yoshioka, Masakata ^a   Gu, Tao ^a   Sasaki, Shinichi ^a   Tominaga, Shigeru ^a   Nishio, Kazuto ^b   Tanabe, Kenneth K ^c   Takahashi, Kazuhisa ^a  

^a JUNTENDO UNIVERSITY   (Japan)

^b NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

CD44s; Chemoresistance; Hyaluronate; MRP2; Non small cell lung cancer

Indexed keywords

BOVINE SERUM ALBUMIN; CISPLATIN; HERMES ANTIGEN; HYALURONIC ACID; MULTIDRUG RESISTANCE PROTEIN 2;

ARTICLE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CELL CULTURE; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL;

ANTIGENS, CD44; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, NON-SMALL-CELL LUNG; CELL ADHESION; CELL LINE, TUMOR; DRUG RESISTANCE, MULTIPLE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; HYALURONIC ACID; IN SITU NICK-END LABELING; LUNG NEOPLASMS; MEMBRANE TRANSPORT PROTEINS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS;

BOVINAE;

EID: 34249327250     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2006.12.025     Document Type: Article

References (30)

1. Pass H., Mitchell J., Johnson D., Turrisi A., and Minnna J. Lung Cancer: Principles and Practice (2000), Lippincott Williams & Wilkins, Philadelphia
2. Socinski M.A., Morris D.E., Masters G.A., and Lilenbaum R. Chemotherapeutic management of stage IV non-small cell lung cancer. Chest 123 (2003) 226S-243S
3. Nishio K., Nakamura T., Koh Y., Suzuki T., Fukumoto H., and Saijo N. Drug resistance in lung cancer. Curr. Opin. Oncol. 11 (1999) 109-115
4. Sethi T., Rintoul R.C., Moore S.M., MacKinnon A.C., Salter D., Choo C., Chilvers E.R., Dransfield I., Donnelly S.C., Strieter R., and Haslett C. Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo. Nat. Med. 5 (1999) 662-668
5. Takahashi K., Stamenkovic I., Cutler M., Dasgupta A., and Tanabe K.K. Keratan sulfate modification of CD44 modulates adhesion to hyaluronate. J. Biol. Chem. 271 (1996) 9490-9496
6. Aruffo A., Stamenkovic I., Melnick M., Underhill C.B., and Seed B. CD44 is the principal cell surface receptor for hyaluronate. Cell 61 (1990) 1303-1313
7. Takahashi K., Takahashi F., Hirama M., Tanabe K.K., and Fukuchi Y. Restoration of CD44S in non-small cell lung cancer cells enhanced their susceptibility to the macrophage cytotoxicity. Lung Cancer 41 (2003) 145-153
8. Takahashi K., Stamenkovic I., Cutler M., Saya H., and Tanabe K.K. CD44 hyaluronate binding influences growth kinetics and tumorigenicity of human colon carcinomas. Oncogene 11 (1995) 2223-2232
9. Bartolazzi A., Nocks A., Aruffo A., Spring F., and Stamenkovic I. Glycosylation of CD44 is implicated in CD44-mediated cell adhesion to hyaluronan. J. Cell Biol. 132 (1996) 1199-1208
10. Bartolazzi A., Peach R., Aruffo A., and Stamenkovic I. Interaction between CD44 and hyaluronate is directly implicated in the regulation of tumor development. J. Exp. Med. 180 (1994) 53-66
11. Bates R.C., Edwards N.S., Burns G.F., and Fisher D.E. A CD44 survival pathway triggers chemoresistance via lyn kinase and phosphoinositide 3-kinase/Akt in colon carcinoma cells. Cancer Res. 61 (2001) 5275-5283
12. Dalton W.S. The tumor microenvironment as a determinant of drug response and resistance. Drug Resist. Updat. 2 (1999) 285-288
13. Morin P.J. Drug resistance and the microenvironment: nature and nurture. Drug Resist Updat. 6 (2003) 169-172
14. Hazlehurst L.A., Argilagos R.F., Emmons M., Boulware D., Beam C.A., Sullivan D.M., and Dalton W.S. Cell adhesion to fibronectin (CAM-DR) influences acquired mitoxantrone resistance in U937 cells. Cancer Res. 66 (2006) 2338-2345
15. Miyamoto H., Murakami T., Tsuchida K., Sugino H., Miyake H., and Tashiro S. Tumor-stroma interaction of human pancreatic cancer: acquired resistance to anticancer drugs and proliferation regulation is dependent on extracellular matrix proteins. Pancreas 28 (2004) 38-44
16. Matsunaga T., Takemoto N., Sato T., Takimoto R., Tanaka I., Fujimi A., Akiyama T., Kuroda H., Kawano Y., Kobune M., Kato J., Hirayama Y., et al. Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia. Nat. Med. 9 (2003) 1158-1165
17. Ohmori T., Nishio K., Ohta S., Kubota N., Adachi M., Komiya K., and Saijo N. Ouabain-resistant non-small-cell lung-cancer cell line shows collateral sensitivity to cis-diamminedichloroplatinum(II) (CDDP). Int. J. Cancer 57 (1994) 111-116
18. Mann S.C., Andrews P.A., and Howell S.B. Modulation of cis-diamminedichloroplatinum(II) accumulation and sensitivity by forskolin and 3-isobutyl-1-methylxanthine in sensitive and resistant human ovarian carcinoma cells. Int. J. Cancer 48 (1991) 866-872
19. Morikage T., Ohmori T., Nishio K., Fujiwara Y., Takeda Y., and Saijo N. Modulation of cisplatin sensitivity and accumulation by amphotericin B in cisplatin-resistant human lung cancer cell lines. Cancer Res. 53 (1993) 3302-3307
20. Gately D.P., and Howell S.B. Cellular accumulation of the anticancer agent cisplatin: a review. Br. J. Cancer 67 (1993) 1171-1176
21. Uchiumi T., Hinoshita E., Haga S., Nakamura T., Tanaka T., Toh S., Furukawa M., Kawabe T., Wada M., Kagotani K., Okumura K., Kohno K., et al. Isolation of a novel human canalicular multispecific organic anion transporter, cMOAT2/MRP3, and its expression in cisplatin-resistant cancer cells with decreased ATP-dependent drug transport. Biochem. Biophys. Res. Commun. 252 (1998) 103-110
22. Haimeur A., Conseil G., Deeley R.G., and Cole S.P. The MRP-related and BCRP/ABCG2 multidrug resistance proteins: biology, substrates specificity and regulation. Curr. Drug Metab. 5 (2004) 21-53
23. Yokomizo A., Kohno K., Wada M., Ono M., Morrow C.S., Cowan K.H., et al. Markedly decreased expression of glutathione S-transferase pi gene in human cancer cell lines resistant to buthionine sulfoximine, an inhibitor of cellular glutathione synthesis. J. Biol. Chem. 270 (1995) 19451-19457
24. Nakagawa K., Yokota J., Wada M., Sasaki Y., Fujiwara Y., Sakai M., et al. Levels of glutathione S transferase pi mRNA in human lung cancer cell lines correlate with the resistance to cisplatin and carboplatin. Jpn. J. Cancer Res. 79 (1988) 301-304
25. Kasahara K., Chida K., Tsunenaga M., Kohno Y., Ikuta T., and Kuroki T. Identification of lamin B2 as a substrate of protein kinase C in BALB/MK-2 mouse keratinocytes. J. Biol. Chem. 266 (1991) 20018-20023
26. Ohga T., Koike K., Ono M., Makino Y., Itagaki Y., Tanimoto M., et al. Role of the human Y box-binding protein YB-1 in cellular sensitivity to the DNA-damaging agents cisplatin, mitomycin C, and ultraviolet light. Cancer Res. 56 (1996) 4224-4228
27. Olaussen K., Dunant D., Fouert P., Brambilla E., Andre F., Haddad V., et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. New Engl. J. Med. 355 (2006) 983-991
28. Zhang Y., Thant A., Machida K., Ichigotani Y., Naito Y., Hiraiwa Y., et al. Hyarulonan-CD44s signaling regulates matrix metalloproteinase-2 secretion in a human lung carcinoma cell line QG90. Cancer Res. 62 (2002) 3962-3965
29. Takahashi K., Eto H., and Tanabe K.K. Involvement of CD44 in matrix metalloproteinase-2 regulation in human melanoma cells. Int. J. Cancer 80 (1999) 387-395
30. Pirinen R., Tammi R., Tammi M., Hirvikoski P., Parkkinen J.J., Johansson R., et al. Prgnostic value of hyaluronan expression in non-small-cell lung cancer: Increased stromal expression indicates unfavorable outcome in patients with adenocarcinoma. Int. J. Cancer 95 (2001) 12-17